Estrogen receptor-a (ERa) is a major therapeutic target of hormonal therapies in breast cancer, and its expression in tumors is predictive of clinical response. Protein levels of ERa are tightly controlled by the 26S proteasome; yet, how the clinical proteasome inhibitor, bortezomib, affects ERa regulation has not been studied. Bortezomib selectively inhibits the chymotrypsin-like activity of the proteasome. Unlike other laboratory proteasome inhibitors, bortezomib failed to stabilize ERa protein at a dose exceeding 90% inhibition of the chymotrypsin-like activity. Unexpectedly, however, chronic bortezomib exposure caused a reduction of ERa levels in multiple ER þ breast cancer cell lines. This response can be explained by the fact that bortezomib induced a dramatic decrease in ERa mRNA because of direct transcriptional inhibition and loss of RNA polymerase II recruitment on the ERa gene promoter. Bortezomib treatment resulted in promoter-specific changes in estrogen-induced gene transcription that related with occupancy of ERa and RNA polymerase II (PolII) on endogenous promoters. In addition, bortezomib inhibited estrogen-dependent growth in soft agar. These results reveal a novel link between proteasome activity and expression of ERa in breast cancer and uncover distinct roles of the chymotrypsin-like activity of the proteasome in the regulation of the ERa pathway.
Introduction
The efficacy of any cancer therapy is dependent on the expression of the molecular targets of those therapies in tumors. One of the most important molecular markers guiding therapy decisions in breast cancer is estrogen receptor-a (ERa), a nuclear receptor that mediates the proliferative actions of estrogen (O'Donnell et al., 2005; DeNardo et al., 2007) . ERa is expressed in approximately 70% of all breast cancers and is increased in both premalignant and malignant lesions (Fabris et al., 1987; Clarke et al., 1997; Shaaban et al., 2002) . It is the major target of current hormonal therapies, and determination of ERa expression by immunohistochemistry is thus common in clinical practice to gauge the differentiation state of the tumor and to predict response to therapies such as aromatase inhibitors, tamoxifen and fulvestrant (Viale et al., 2007; Robertson et al., 2009) . Evidence also suggests that expression of ERa in tumors is dynamic and can change during the course of tumor progression and after therapy (Nomura et al., 1985; Liedtke et al., 2009) .
A major regulatory pathway governing ERa protein expression is the ubiquitin-proteasome pathway. This pathway controls the stability of ERa protein through the covalent attachment of ubiquitin moieties to the receptor that then targets it to the 26S proteasome for degradation. Multiple signals, including estrogen binding, result in increased ubiquitination of ERa and its subsequent proteolysis (Alarid et al., 1999; El Khissiin and Leclercq, 1999; Nawaz et al., 1999; Wijayaratne and McDonnell, 2001) . The loss of this response is associated with an increased risk of breast cancer and hormone insensitivity associated with metastasis (Khan et al., 1999; Harrell et al., 2007) .
The 26S proteasome is a multisubunit protease that functions as the major regulator of all short-lived proteins in cells (Rock et al., 1994) . It comprises two 19S regulatory complexes and a 20S core complex. The 20S core constitutes the major proteolytic activity of the proteasome, and comprises a-and b-subunits, which are organized into four rings of seven subunits each. The b-subunits (b1, b2 and b5) possess distinct protease activities based upon the cleavage site in the protein substrate (Orlowski and Wilk, 1981) . The b1 and b2 subunits possess the peptidyl glutamyl hydrolase-like and trypsin-like activities, respectively. The b5 subunit contains the chymotrypsin-like activity, which is considered the dominant protease activity (Heinemeyer et al., 1997) .
Although the 26S proteasome is a critical regulator in all cells, cancer cells may be more dependent on proteasome activity. Proteasome subunits are upregulated in gastric, breast and ovarian cancers as well as in leukemia (Kumatori et al., 1990; Bossola et al., 2003; Chen and Madura, 2005; Bazzaro et al., 2006) . In breast cancer, a 'proteasome signature' was identified that is predictive of poor outcome (Wong et al., 2008) . In addition to changes in proteasome gene expression, the activity of the 26S proteasome was shown to be increased in primary breast tumors relative to normal adjacent tissue (Chen and Madura, 2005) and in invasive breast cancer cell lines relative to non-tumorigenic MCF10 cells (Xu et al., 2008) . Cumulatively, this evidence has suggested the possible benefit of inhibitors of 26S proteasome as anticancer agents.
In an effort to develop clinical proteasome inhibitors, drugs have been developed that target individual protease activities of the proteasome. Common proteasome inhibitors, such as MG132, target all three catalytic activities (Taggart et al., 2002) . Bortezomib is the Food and Drug Administration-approved proteasome inhibitor that selectively inhibits the chymotrypsin-like activity (Kisselev et al., 2006) . It is currently in clinical use and shows efficacy in the treatment of multiple myeloma and mantle cell lymphoma as a single agent and in combination with other drugs for both refractory and relapsed disease (Richardson et al., 2006) . Given the critical role of the 26S proteasome in ERa protein regulation and the importance of ERa in therapy decisions for the treatment of breast cancer, we sought to examine the effects of bortezomib on ERa regulation and function in hormone-responsive tumor cells.
Results
The chymotrypsin-like activity of the 26S proteasome is not required for ligand-inducible degradation of ERa protein Dose-response curves were conducted initially to establish the doses of bortezomib that are necessary to inhibit the chymotrypsin-like activity in a panel of cells derived from estrogen-responsive tissues. The cell lines tested include representative lines of the major classes of breast cancer: luminal A (MCF7, T47D), luminal B (BT474) and triple negative (MDA-MB-231). Additional ER þ cells derived from endometrial cancer (ECC1) and pituitary hyperplasia (PR1) were also included. Cells were treated with bortezomib ranging from 0 to 70 nM for 4 h and chymotrypsin-like activity was determined using luminescent enzyme assay that reports cleavage of a luminescent Suc-LLVY peptide. Table 1 shows that bortezomib inhibits 50% of the chymotrypsin-like activity at doses below 10 nM in the cell lines tested. A comparison of the inhibitory activity of bortezomib and MG132 in MCF7 cells shows that inhibition of 95% of the chymotrypsinlike activity is achieved with 30 nM bortezomib (Figure 1a ), whereas 10 mM MG132 is necessary to reach equivalent levels of inhibition (Figure 1b ). These data show that bortezomib is more efficacious than MG132 and are consistent with the increased selectivity of bortezomib against the chymotrypsin-like activity of the proteasome relative to general proteasome inhibitors.
We, and others, previously showed that ERa protein is rapidly degraded in response to 17-b-estradiol (E2) treatment through a proteasome-dependent pathway. Proteasome inhibitors, including N-acetyl leucyl-leucyl norlucinal, MG132 and lactacystin, were shown to abrogate ligand-induced receptor degradation in a dose-dependent manner (Alarid et al., 1999 ; El Khissiin and Leclercq, 1999; Nawaz et al., 1999; Reid et al., 2003) .
To establish the role of the chymotrypsin-like activity in estrogen-induced regulation of ERa protein, MCF7 cells were pretreated for 30 min with 30 nM bortezomib or 10 mM MG132, followed by treatment with 10 nM E2 or vehicle for 4 h. In agreement with previous reports, estrogen treatment resulted in a loss of ERa protein that was prevented by MG132 ( Figure 1d) . Surprisingly, bortezomib treatment was without effect on estrogentreated cells (Figure 1c ). p53 protein levels were increased in the presence of MG132 and bortezomib, indicating that both inhibitors were active and prevented the constitutive degradation of p53 (Maki et al., 1996) . Similar results were observed in other estrogen-responsive cells, T47D, ECC1 and PR1 (Supplementary Figures 1a-c) . Dose-response studies were then extended to determine whether higher doses of bortezomib were required to inhibit ERa proteolysis. MCF7 cells were treated with bortezomib ranging from 0 to 500 nM in the presence or absence of E2 as above. Figure 2 shows that bortezomib partially prevents estrogen-induced proteolysis at 100 nM but complete inhibition is achieved at 500 nM bortezomib. At higher doses, the inhibitory activity of bortezomib expands beyond the chymotrypsin-like site. Indeed, 500 nM bortezomib was shown to also inhibit the caspase-like and trypsin-like activities (Kisselev et al., 2006) . Thus, it is unlikely that the stabilization of ERa protein at high concentrations of bortezomib is due to blockade of chymotrypsin-like activity alone. Rather, a more plausible explanation is that stabilization of ERa protein requires multiple enzymatic activities of the proteasome, and that the inhibition of the chymotrypsin-like activity is insufficient to block the rapid degradation of receptor induced upon ligand binding.
Chronic chymotrypsin-like inhibition results in the loss of ERa in ER þ cells Proteasome-dependent regulation of ERa is a timedependent process with observable differences between short and chronic treatments with estrogen (Valley et al., 2008) . Bortezomib is administered chronically, as patients are treated with bortezomib every 3 days and proteasome inhibition in the blood persists 24 h after treatment (Shah et al., 2004) . The effect of long-term exposure to bortezomib was thus examined. MCF7 cells were treated with 30 nM bortezomib for 24 h in the presence and absence of estrogen. Surprisingly, by 24 h, ERa protein was dramatically diminished in both the presence of bortezomib and MG132 ( Figure 3 ) relative to vehicle controls. Estrogen treatment similarly decreased ERa levels and this loss could be partially stabilized by MG132, but not by bortezomib. p53 levels were increased with both inhibitors and were induced by estrogen, consistent with results shown above and previous published reports, respectively (Qin et al., 2002) . Western blot analysis of ERa levels in other ER þ cells under identical conditions showed that ERa protein loss induced by bortezomib was a generalized response ( Supplementary Figures 1d-g ).
Estrogen receptor-a protein levels under conditions of constant exposure to estrogen are largely controlled at the level of receptor synthesis (Valley et al., 2008) . ERa mRNA levels were therefore examined after bortezomib treatment. Evaluation of ERa mRNA levels using quantitative real-time PCR (qRT-PCR) showed that treatment with bortezomib caused a decrease in ERa mRNA to 18%±0.01 of control levels. E2 also reduced ERa mRNA and a combined treatment with bortezomib and E2 results in an approximate 94% ± 0.01 decrease in ERa mRNA expression relative to vehicletreated controls (Figure 4a ). ERb mRNA levels were not significantly altered by either E2 or bortezomib alone, but in combination, estrogen and bortezomib increased ERb mRNA (Figure 4b ). Bortezomib also increased expression of the a5 subunit of the proteasome (Figure 4c ), providing further evidence that the effect of bortezomib on ERa gene expression was specific and not due to general inhibition of transcription.
To probe further into the mechanism of bortezomibinduced decrease in ERa, levels of nascent unspliced ERa mRNA were evaluated using qRT-PCR. Similar to total ERa mRNA, the nascent transcript was decreased approximately 90±0.03% by bortezomib alone and was further reduced by an additional 7±0.01% by E2. In total, ERa transcription was reduced to 3% of the levels in control cells by bortezomib in the presence of estrogen ( Figure 5a ). Chromatin immunoprecipitation (ChIP) was performed to examine RNA polymerase II (RNA PolII) occupancy as an independent measure of transcription. Previous studies in our laboratory and those of others showed that the major promoter governing ERa gene expression in MCF7 breast cancer cells is the A promoter located near the transcription start site Ellison-Zelski et al., 2009) . Studies in Figure 5b show that RNA PolII is present on the A promoter and exon 1, with negligible occupancy at a non-specific site at À940 basepairs upstream of the transcription start site. These results are consistent with the active transcription of the ERa gene in MCF7 cells. Paralleling the loss of nascent transcript, bortezomib and estrogen treatments both resulted in a decrease in RNA PolII occupancy at both the A promoter and exon 1. These data indicate that bortezomib regulates ERa directly at the transcriptional level by reducing RNA PolII occupancy at the proximal promoter. The data suggest that bortezomib regulation of ERa gene transcription is dependent on the endogenous ERa promoter. To test this further, C4-12 breast cancer cells, an ERÀ derivative of the MCF7 cells, were engineered to express wild-type-ERa under the control of a cytomegalovirus promoter. qRT-PCR for ERa mRNA driven by a heterologous promoter showed that, in contrast to the endogenous gene, cytomegalovirus-driven ERa mRNA levels were increased by bortezomib (Figure 6a ). The lack of effect by estrogen is expected as estrogen regulation of ERa requires the native chromatin environment (EllisonZelski et al., 2009 ). Analysis of wild-type-ERa protein levels showed that chronic bortezomib also did not deplete ERa protein under these conditions (Figure 6b ). These data reveal that bortezomib inhibits transcription of ERa mRNA through mechanisms involving the endogenous regulatory region. Moreover, they suggest that the loss of ERa protein observed in cell lines upon chronic bortezomib exposure can be explained by the inhibition of ERa mRNA transcription.
The loss of ERa protein with chronic proteasome inhibition alters ERa functional activity Next, the effect of bortezomib on ERa functional activity was assessed. The transcriptional activity of ERa was evaluated by analysis of endogenous progesterone receptor (PR) and pS2 gene expression. PR and pS2 are classical Figure 4 for the nascent ERa transcript. The data were analyzed relative to the average ethanol (EtOH) treatment and the mean of three independent experiments is shown. Statistics were performed to show significant differences (Po0.05) between vehicle control and estrogen and are marked a and b, respectively. (b) Chromatin immunoprecipitation (ChIP) was performed using antibodies for RNA PolII and immunoglobulin G (IgG). Primers for non-specific (NS), the A promoter (A) and exon 1 (Ex1) regions of the ERa promoter were used with qRT-PCR to examine the occupancy at each site. Data are presented as the mean percent input of three independent experiments. Error bars represent s.e.m.
bortezomib treatment had opposite effects on these two estrogen receptor target genes. Bortezomib treatment resulted in a significant inhibition of estrogen-dependent activation of PR, whereas it resulted in an enhancement of estrogen-dependent pS2 gene transcription (Figures  7a and b) . In the absence of estrogen, bortezomib decreased pS2 and increased PR gene expression. An artificial reporter gene consisting of tandem estrogen response elements and a minimal thymidine kinase promoter was also analyzed to directly test the effect of bortezomib on ERa-dependent transcription. Luciferase protein and gene expression were significantly increased by estrogen treatment and this was unaffected by co-treatment with bortezomib (Figures 7c and d) . Bortezomib also did not affect basal luciferase levels, indicating that the thymidine kinase promoter was not sensitive to proteasome inhibition. These data suggest that bortezomib alters ERa-dependent gene transcription in a promoter-specific manner.
Chromatin immunoprecipitation analysis was undertaken to determine whether the differences observed between PR and pS2 were related to the level of ERa occupancy on the promoters. In Table 2 , the occupancy of RNA PolII and ERa on the pS2 and PR promoters can be compared with the changes in expression levels in each treatment group. RNA PolII occupancy on the two promoters follows the transcription of the genes. Occupancy of RNA PolII on both PR and pS2 promoters increased in response to estrogen. RNA PolII remains elevated on the pS2 promoter in the presence of bortezomib, but is decreased on the PR promoter. This is consistent with high levels of expression of pS2 and loss of expression of PR in the presence of bortezomib. Similarly, ERa occupancy increased on both promoters in response to estrogen. Most striking, however, is the ERa occupancy on the two promoters in the presence of bortezomib. Despite a severe reduction in ERa protein levels in the presence of bortezomib (Figure 3) , ERa occupancy on the pS2 gene is unaffected, whereas ERa occupancy on PR is decreased. These results show that the promoter-specific actions of bortezomib on ERamediated gene transcription relate to ERa occupancy on the promoters and the sensitivity of individual target genes to changes in ERa levels.
Estrogen receptor-a is a major regulator of growth in estrogen-dependent tumor cells. Inhibitors of ERa activity are effective therapies in breast cancer and inhibit proliferation both in vitro and in vivo (Wakeling et al., 1991) . In particular, fulvestrant is a potent antiestrogen therapeutic that depletes cells of receptor by targeting ERa protein for degradation (Dauvois et al., 1993) . Given the loss of ERa protein with bortezomib, it could be predicted that bortezomib would similarly inhibit estrogen-induced growth. Soft agar proliferation assays were conducted to establish the effect of bortezomib on estrogen-induced anchorage-independent colony formation. As expected, estrogen stimulated anchorage-independent growth. However, in the presence of estrogen and bortezomib, colony formation was reduced to approximately 3% of that observed with estrogen alone (Figure 8) . Thus, bortezomib, in the presence of estrogen, decreased anchorage-independent growth and antagonized estrogen-dependent proliferation similar to other ERa antagonists (DeFriend et al. 
Discussion
Control of ERa levels and activity is of paramount importance in breast cancer. It is established that this control is in part mediated through the regulation of receptor protein stability by the 26S proteasome. The data presented in this study indicate that the role of the proteasome in ERa signaling extends beyond the control of protein turnover. Our data reveal that the inhibition of the chymotrypsin-like activity of the proteasome is not necessary for estrogen-induced degradation of ERa protein, but instead directly regulates the expression of ERa gene. This results in downstream consequences on ERa-mediated transcription. In addition, inhibition of the proteasome prevents estrogen-dependent growth of breast cancer cells. These findings reveal that specific enzymatic activities have differential roles in the control of ERa protein and estrogen-dependent responses. Bortezomib was developed as a selective inhibitor of the chymotrypsin-like activity of the 26S proteasome. This specificity allowed us to probe more deeply into the activities of the proteasome that contribute to hormoneinducible degradation of ERa. A surprising finding was the inability of bortezomib to inhibit ligand-activated ERa degradation. This is in contrast with other proteasome inhibitors, such as MG132, which has been used extensively by us and others to show stabilization of ERa protein (Alarid et al., 1999; El Khissiin and Leclercq, 1999; Nawaz et al., 1999; Alarid, 2006) . Doses that are two orders of magnitude greater than those required to inhibit 95% of the chymotrypsin-like activity were required to prevent receptor degradation. Therefore, it is likely that other activities of the 26S proteasome have a larger role in ERa protein stability, and that the chymotrypsin-like activity is not required. Inhibitors developed to target the chymotrypsin-like activity will not prevent the rapid degradation of ERa protein that constitutes the autoregulatory negative feedback loop controlling sensitivity to estrogen, but they will have long-term effects on ERa signaling in cells that depend on ERa expression.
Bortezomib had dramatic effects on ERa protein and it functions at 24 h. Indeed, ERa protein was significantly depleted in bortezomib-treated cells. The loss of protein after chronic bortezomib is due to >90% of the repression of ERa gene transcription. This is a direct transcriptional effect of bortezomib on ERa gene expression. ERa gene, ESR1, is 450 kb in size and is regulated by seven different promoters, A-E2, that yield different transcripts, making it one of the most complex genes in the genome . How the different promoters interact and coregulate ERa expression has not been elucidated. Moreover, the molecular mechanisms that repress ERa gene regulation are only beginning to be elucidated (Adams et al., 2007; Abbreviations: ChIP, chromatin immunoprecipitation; E2, 17-b-estradiol; E2/B, E2/bortezomib; ERa, estrogen receptor-a; EtOH, ethanol; IgG, immunoglobulin G; PolII, polymerase II; PR, progesterone receptor. The recruitment of RNA PolII and ERa on the pS2 and PR promoters in the presence of estrogen and bortezomib corresponds to the transcriptional response. MCF7 cells were treated for 30 min with 30 nM bortezomib followed by 10 nM E2 for 24 h. Cells were fixed, lysed, sonicated, and immunoprecipitated with antibodies for RNA polymerase II (RNA PolII), ERa, and IgG as a specificity control. Data are presented as the mean percent input±the standard error of the mean of three independent experiments. Statistically significant differences (Po0.05) were determined using the Student's t-test and are denoted with a (relative to EtOH) or b (relative to 17-b-estradiol (E2)). Dhasarathy et al., 2007; Han et al., 2008; Kondo et al., 2008; Ellison-Zelski et al., 2009; Pandey and Picard, 2009; Wang et al., 2009) . Regulation of ERa by bortezomib involves loss of RNA PolII at the proximal promoter region. Our laboratory reported that estrogen repression of ERa involves specific chromatin modifications in both the A promoter and exon 1 (Ellison-Zelski et al., 2009). We observed that the combined effects of bortezomib and estrogen on ERa gene transcription is greater than either treatment alone (Figure 5a ), and thus bortezomib is unlikely to repress ERa through the same mechanism. Elucidating the mechanism of proteasome-dependent ERa gene transcription is a subject of on-going experimentation. Similar to ERa protein, the effects of bortezomib on ERa-mediated transcription are delayed. Activated genes, PR and pS2, were inversely affected by bortezomib, but only after prolonged bortezomib treatment. Estrogen induction of PR and pS2 were not altered by bortezomib at 4 h (data not shown). Similar variable effects on ERa-mediated gene transcription have been reported after MG132 treatment at various time points (Lonard et al., 2000; Reid et al., 2003; Fan et al., 2004) . The delayed transcriptional response suggested that the actions of bortezomib on ERa-mediated transcription are indirect and are most likely secondary to effects on ERa protein. ChIP analysis of RNA PolII and ERa occupancy on these genes revealed that indeed the relative expression of these genes is related with the occupancy of ERa and RNA PolII on these promoters. An interesting observation is that loss of ERa protein did not result in a uniform decrease in occupancy of ERa at all ERa target genes. ERa occupancy on the pS2 promoter was not diminished despite the severe depletion of ERa from the cells. This suggests that pS2 is less sensitive than PR to changes in ERa levels. Moreover, it points to the potential for promoter-specific requirements for different amounts of ERa protein for sustained activation.
The results of these studies have implications in breast cancer therapy and progression. Hormonal therapies antagonize the actions of ERa. Current clinical antagonists include aromatase inhibitors, tamoxifen and fulvestrant (Coates et al., 2007; Chia et al., 2008) . Each functions through a distinct mechanism providing increased patient options and the potential for sequential therapeutic approaches. Aromatase inhibitors block ligand synthesis, tamoxifen inhibits ERa transcriptional function and fulvestrant degrades ERa protein (Jordan, 1976; Dowsett et al., 1985; Parker, 1993; Viale et al., 2007) . Bortezomib functions through yet another distinct mechanism, that is, inhibition of ERa gene expression. Anchorage-independent growth of breast cancer cells is inhibited by bortezomib, consistent with reports in other in vitro and in vivo models (Teicher et al., 1999; Marx et al., 2007) . These studies expand on the previous studies with focus on estrogen-dependent growth. The data indicate that bortezomib can significantly decrease growth in the presence of estrogen, similar to tamoxifen and ICI182780 (DeFriend et al., 1994) . The effectiveness of bortezomib as a single agent in solid tumors, however, has thus far been disappointing (Shah et al., 2004; Yang et al., 2006; Engel et al., 2007) . Nevertheless, these data, along with that from other preclinical models (Cardoso et al., 2006; Marx et al., 2007; Wong et al., 2008) , support the potential for proteasome inhibition as a viable route for development of new therapeutics for ER þ breast cancer.
In addition to its role as a predictive marker for therapy, ERa expression is also a marker for other changes associated with cancer progression. The percentage and intensity of ERa expression are increased in premalignant and malignant lesions relative to the normal mammary gland. ERa protein and mRNA is elevated in hyperplastic enlarged lobular units, a potential precursor to breast cancer . ERa expression is also increased in atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ and invasive carcinomas (Shoker et al., 1999; Shaaban et al., 2002) . The mechanism underlying the expansion of ER þ cells is unknown. Studies in Figure 3 and Supplementary data suggest that proteasome activity sustains ERa expression in multiple estrogen-responsive cells as inhibition of this activity leads to a loss of ERa mRNA. This suggests the possibility that increased ERa expression in early lesions may result from changes in proteasome activity. This notion is supported by evidence that protein levels of proteasome subunits and chymotrypsin-like activity are increased in tumor samples relative to normal adjacent tissue (Chen and Madura, 2005) . In addition, proteasome activity in ER þ cell lines is approximately twice that found in ERÀ cell lines (Codony-Servat et al., 2006) . The association between proteasome activity and ERa expression in breast cancer, as revealed by this study, suggests the potential that proteasome function could contribute to multiple levels of breast cancer progression, including induction of differentiation of ERÀ cells and/or driving the selective advantage of ER þ cells in malignancy. Examination of proteasome activity in early premalignant lesions would lend insight into this possibility.
In conclusion, this study shows that bortezomib, the Food and Drug Administration-approved anticancer agent, has significant and broad effects on the ERa pathway in breast cancer cells. Bortezomib does not interfere with the rapid response of estrogen-induced proteolysis of the receptor by the 26S proteasome, but chronically, it inhibits expression of ERa and PR genes as well as ERa protein. In addition, bortezomib was found to inhibit estrogen-dependent colony formation in breast cancer cells. These studies highlight the complexity of ERa regulation by the 26S proteasome and reveal a new link between the proteasome pathway and ER þ breast cancer.
Materials and methods

Cell culture
Cells were maintained in media containing phenol red and L-glutamine supplemented with 10% fetal bovine serum (Biowest, Miami, FL, USA) and 100 units/ml of penicillin and 100 mg/ml streptomycin, unless otherwise indicated. Reagents were from Gibco/Invitrogen (Carlsbad, CA, USA) unless indicated. MCF7, PR1 and MDA-MB-231 were cultured in high glucose Dulbecco's modied Eagle's medium (Mediatech, Inc., Herndon, VA, USA). T47D cells were maintained in RPMI 1640 (Mediatech). ECC1 and BT474 cells were cultured in Dulbecco's modied Eagle's medium/F12. BT474 cells were supplemented with 2 mM L-glutamine, 0.1 mM non-essential amino acids and 6 ng/ml insulin (Sigma-Aldrich Corp., St Louis, MO, USA). Wild-type-ERa cell lines were generated and maintained as previously described (Oesterreich et al., 2001 ).
Hormone and proteasome inhibitor treatments At 3 days before experiments, cells were transferred to phenol red-free media supplemented with 10% charcoal dextranstripped fetal bovine serum, penicillin/streptomycin and 4 mM L-glutamine. Cells were pre-treated 30 min with proteasome inhibitors MG132 (Calbiochem, Gibbstown, NJ, USA) or Bortezomib (gift from Dr Shigeki Miyamoto) followed by vehicle (0.1% ethanol) or 10 nM E2 (Steraloids, Inc., Newport, RI, USA) as indicated.
Determination of the half-maximal inhibitory concentration A total of 50 000 cells/well were plated in a 96-well plate. Increasing concentrations of bortezomib from 0 to 70 nM or MG132 from 0 to 10 mM were incubated with the cells for 4 h. Chymotrypsin-like activity of the proteasome was measured with a luminescent enzyme assay according to the manufacturer's instructions (Promega, Madison, WI, USA) and read using a Victor plate reader (PerkinElmer, Waltham, MA, USA). Luminescent signal was assessed relative to untreated cells. Data are representative of a minimum of two experiments performed in duplicate. Half-maximal inhibitory concentration calculations were completed using nonlinear regression analysis in Graphpad Prism version 5.0 (San Diego, CA, USA).
Western blots
Western blots were performed as described previously (Valley et al., 2008) . Blots were probed with antibodies for ERa (6F11, Vector Laboratories Inc., Burlingame, CA, USA), p53 (DO 1, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and bactin (Sigma-Aldrich Corp.). Anti-mouse horseradish peroxidaseconjugated secondary antibody was used after primary antibody incubation (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). Enhanced chemiluminescence was used for visualization. Representative blots of a minimum of two independent experiments, showing consistent results, are shown in figures.
Luciferase assay MCF7 cells were transfected using lipofectamine 2000 (Invitrogen) with ERE-tk-luc (3 estrogen response elements upstream of a thymidine kinase promoter with luciferase cDNA sequence) and cytomegalovirus-b-galactosidase plasmids for 24 h and then treated as indicated. Luciferase and b-galactosidase assays were performed as described previously (Fowler et al., 2006) .
Quantitative real-time PCR (qRT-PCR)
Total RNA isolation, reverse transcription and qRT-PCR were performed as previously described (Valley et al., 2008) . Ribosomal protein P0 mRNA served as the internal control. Primer sequences are shown in Table 3 .
Relative RNA levels were calculated using the DC t method (Livak and Schmittgen, 2001) . Statistics were performed using the MStat program (McArdle Laboratory for Cancer Research, Madison, WI, USA) with the Wilcoxon signed-rank test (Yuan et al., 2006) .
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation and qRT-PCR were performed as previously described (Ellison-Zelski et al., 2009 ). The antibodies used were ERa (HC-20 sc-543) and immunoglobulin G (sc 2027) from Santa Cruz and RNA PolII (PolII 8WG16) from Covance (Emeryville, CA, USA). Primer sequences are listed in Table 4 .
Soft agar assay A total of 2 ml of 0.8% sea plaque agarose (Cambrex, Rockland, ME) was added to a six-well plate. The following day, 250 000 estrogen-deprived MCF7 cells were suspended in 0.4% agarose/media with 10 nM estrogen ±30 nM bortezomib. Cells were plated on top of the previously poured layers. Treatments were replaced after every 4 days. After 14 days, colonies were stained with crystal violet, imaged and counted using a gel doc XR (Bio-Rad, Hercules, CA, USA). 
